First subcutaneous Hemophilia A treatment is approved for people with or without inhibitors
On October 4, 2018, the Food and Drug Administration approved emicizumab-kxwh injection for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.
This treatment was first approved in 2017, but only for people with inhibitors.
Unlike previous treatments, this treatment does not contain factor VIII. Instead, it relies on a synthetic enzyme that replicates the function of factor VIII.
